This database contains 145 studies, archived under the term: "patients"
Click here to filter this large number of results.
Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer’s disease and AD + DLB
Nelson, Peter T.,
Kryscio, Richard J.,
Abner, Erin L.,
Schmitt, Frederick A.,
Jicha, Gregory A.,
Mendiondo, Marta S.,
Cooper, Greg,
Smith, Charles B.,
Markesbery, William R.
Dementia can be caused by different diseases including Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), or both (AD + DLB). University of Kentucky AD Center pathologically-diagnosed AD and AD + DLB cases were evaluated who had three or more longitudinal antemortem mental status examinations (n = 156). Patients with important concomitant pathology (n = […]
Long-term treatment of patients with Alzheimer’s disease in primary and secondary care: Results from an international survey
Froelich, Lutz,
Andreasen, Niels,
Tsolaki, Magda,
Foucher, Arnaud,
Kavanagh, Shane,
Van Baelen, Bart,
Schwalen, Susanne
Objective: The International Outcomes Survey in Dementia (IOSID) was initiated to observe the effects of current standard of care for Alzheimer’s disease (AD) on patient outcomes and caregiver burden in a real-life setting. Research design and methods: This 2-year, international, prospective, longitudinal and observational cohort survey involved patients with mild-to-moderate AD (Mini-Mental State Examination [MMSE] […]
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial
Cummings, J. L.,
Lyketsos, C. G.,
Peskind, E. R.,
Porsteinsson, A. P.,
Mintzer, J. E.,
Scharre, D. W.,
De La Gandara, J. E.,
Agronin, M.,
Davis, C. S.,
Nguyen, U.,
Shin, P.,
Tariot, P. N.,
Siffert, J.
IMPORTANCE: Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking. OBJECTIVE: To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation. DESIGN, SETTING, AND PARTICIPANTS: Phase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequential parallel comparison design with 2 consecutive 5-week treatment stages conducted August […]
Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial)
Ballard, Clive,
Brown, Richard,
Fossey, Jane,
Douglas, Simon,
Bradley, Paul,
Hancock, Judith,
James, Ian A.,
Juszczak, Edmund,
Bentham, Peter,
Burns, Alistair,
Lindesay, James,
Jacoby, Robin,
O'Brien, John,
Bullock, Roger,
Johnson, Tony,
Holmes, Clive,
Howard, Robert
Background: Good practice guidelines state that a psychological intervention should usually precede pharmacotherapy, but there are no data evaluating the feasibility of psychological interventions used in this way. Methods: At the first stage of a randomized blinded placebo-controlled trial, 318 patients with Alzheimer disease (AD) with clinically significant agitated behavior were treated in an open […]
Efficacy and safety of cerebrolysin in moderate to moderately severe Alzheimer’s disease: Results of a randomized, double‐blind, controlled trial investigating three dosages of cerebrolysin
Alvarez, X. A.,
Cacabelos, R.,
Sampedro, C.,
Aleixandre, M.,
Linares, C.,
Granizo, E.,
Doppler, E.,
Moessler, H.
Background: Cerebrolysin is a neuropeptide preparation mimicking the effects of neurotrophic factors. This subgroup analysis assessed safety and efficacy of Cerebrolysin in patients with moderate to moderately severe Alzheimer’s disease (AD) (ITT data set: N = 133; MMSE: 14–20) included in a dose‐finding study (ITT data set: N = 251; MMSE: 14–25). Results of the […]
Effects of Chinese medicine for promoting blood circulation and removing blood stasis in treating patients with mild to moderate vascular dementia: a randomized, double-blind and parallel-controlled trial
Wei, Ming-qing,
Tian, Jin-zhou,
Shi, Jing,
Ma, Fu-yun,
Miao, Ying-chun,
Wang, Yong-yan
Background: Vascular dementia (VaD) is the second common subtype of dementia after Alzheimer’s disease. However, there is still a lack of medication that demonstrates clinically relevant symptomatic improvement. Static blood obstructing the brain is the main Chinese medicine syndrome of VaD.; Objective: To evaluate the effects of Chinese medicine for promoting blood circulation and removing […]